Suppr超能文献

接受 PCI 治疗的 ACS 合并糖尿病患者应用氯吡格雷的治疗结局:北京市医疗保险数据库分析。

Treatment Outcomes of Clopidogrel in Patients With ACS and Diabetes Undergoing PCI-Analysis of Beijing Municipal Medical Insurance Database.

机构信息

Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing, China.

出版信息

Front Endocrinol (Lausanne). 2021 Jul 30;12:713849. doi: 10.3389/fendo.2021.713849. eCollection 2021.

Abstract

BACKGROUND AND AIMS

Several clinical trials have proved the efficacy of clopidogrel treatment for patients with percutaneous coronary intervention. There are few large-scale studies to identify the mortality associated with different durations of treatment of clopidogrel in patients with diabetes and ACS undergoing PCI in the Chinese population. The objective of this analysis was to determine the efficacy of long-term clopidogrel therapy (≥12 months) short-term use (<12 months) in Chinese patients with diabetes after PCI.

METHODS AND RESULTS

We used the Beijing Municipal Medical Insurance Database provided by the Beijing Municipal Medical Insurance Bureau. The Beijing Municipal Medical Insurance Database contained medical data of about 16 million people, including about 990,000 patients with diabetes and a history of taking antidiabetic medicines. Patients were divided into two groups, one group of 9,116 patients receiving consecutive clopidogrel for one year or more, and another group of 3290 patients receiving consecutive clopidogrel for less than one year. The primary outcomes of this analysis were the risk of all-cause death, myocardial infarction, and revascularization. In patients with diabetes after PCI, long-term clopidogrel treatment was associated with a reduced risk of all-cause death (HR, 0.57[95%CI, 0.49-0.67], P<0.0001), myocardial infarction (HR, 0.79[95%CI, 0.68-0.93], P=0.0035) and an increased risk of angina (HR, 1.18[95%CI, 1.10-1.27], P<0.0001]) and revascularization (HR, 1.07[95%CI, 1.01-1.13], P=0.02]). There was no significant difference in the prevalence of all-cause re-hospitalization, diabetes-related re-hospitalization, and cerebrovascular re-hospitalization.

CONCLUSION

The present study concluded that long-term dual antiplatelet therapy including clopidogrel and aspirin could decrease the risks of all-cause death, myocardial infarction. But it could increase the risks of angina and revascularization. Further studies should interpret the cause of this question.

摘要

背景与目的

多项临床试验已经证实氯吡格雷治疗经皮冠状动脉介入治疗患者的疗效。在中国人群中,很少有大规模的研究来确定糖尿病合并急性冠脉综合征患者接受经皮冠状动脉介入治疗后不同氯吡格雷治疗时间的死亡率。本分析的目的是确定中国糖尿病患者经皮冠状动脉介入治疗后长期(≥12 个月)氯吡格雷治疗(短期使用(<12 个月)的疗效。

方法与结果

我们使用了北京市医疗保险局提供的北京市医疗保险数据库。该数据库包含了约 1600 万人的医疗数据,其中包括约 99 万名患有糖尿病且正在服用降糖药物的患者。患者被分为两组,一组为 9116 例连续服用氯吡格雷一年或以上的患者,另一组为 3290 例连续服用氯吡格雷不到一年的患者。本分析的主要终点为全因死亡、心肌梗死和血运重建的风险。在接受经皮冠状动脉介入治疗后的糖尿病患者中,长期氯吡格雷治疗与全因死亡风险降低相关(HR,0.57[95%CI,0.49-0.67],P<0.0001)、心肌梗死(HR,0.79[95%CI,0.68-0.93],P=0.0035)和心绞痛风险增加(HR,1.18[95%CI,1.10-1.27],P<0.0001)和血运重建(HR,1.07[95%CI,1.01-1.13],P=0.02])。全因再住院、糖尿病相关再住院和脑血管再住院的发生率无显著差异。

结论

本研究表明,包括氯吡格雷和阿司匹林在内的长期双联抗血小板治疗可以降低全因死亡、心肌梗死的风险。但它可能会增加心绞痛和血运重建的风险。进一步的研究应该解释这个问题的原因。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2cdc/8362599/effd1bd76bca/fendo-12-713849-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验